Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease
Abstract
Background Renal dyslipoproteinemia is characterized by the accumulation of intact and partially metabolized triglyceride-rich lipoproteins. Reduced lipolytic enzyme activities may be one of the major pathophysiological mechanisms contributing to a retarded catabolism of these lipoproteins in patients with renal insufficiency. Objective To evaluate the effect of gemfibrozil treatment on renal dyslipoproteinemia. Study design A randomized, controlled open study with 2 parallel groups. Outcome variables Plasma concentrations of lipids, apolipoproteins and lipoprotein particles. Patients and methods Fifty-seven non-nephrotic, non-diabetic patients with moderately advanced renal insufficiency were randomized to either treatment with gemfibrozil at dosages from 300 to 900 mg/day (n = 28) or dietary counseling (n = 29). The intervention period was 12 months. Plasma concentrations of lipids, apolipoproteins and apoA- and apoB-containing lipoprotein particles were determined at the entry and after 6 and 12 months of treatment. Results No serious adverse effects occurred during the study. Six patients experienced mild gastrointestinal symptoms and prematurely withdrew from the drug treatment. In the group treated with gemfibrozil the plasma concentrations of triglycerides, total cholesterol, very low density lipoprotein (VLDL) and low density (LDL) cholesterol decreased significantly by 47, 13, 43 and 14%, respectively, in comparison to baseline. High density lipoprotein (HDL) cholest…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Overall, 4 trials had a Jadad score of 4, 1 scored 3, 2 scored 2, and 1 scored 1.
“Overall, 4 trials had a Jadad score of 4 (24,25,32,35), 1 scored 3 (33), 2 scored 2 (29,31), and 1 scored 1 (30).”
From Effects of Fibrates in Kidney Disease (2012) · cites this paper as [31]
Cites
Still being checked.
Cited by
Sorted by citations
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Hegbrant, J., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub2 · Cited by 334 · see citing works
Effects of Fibrates in Kidney Disease
Jun, M., Zhu, B., Tonelli, M., Jardine, M. J., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., & Perkovic, V. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.049 · Cited by 189 · see citing works
Qaseem, A., HOPKINS, R. H., Sweet, D. E., Starkey, M., & Shekelle, P. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-12-201312170-00726 · Cited by 179 · see citing works
Fibrate‐induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
Broeders, N., Knoop, C., Antoine, M., Tielemans, C., & Abramowicz, D. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.12.1993 · Cited by 163 · see citing works
Fibrates, dyslipoproteinaemia and cardiovascular disease
Watts, G. F., & Dimmitt, S. B. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199912000-00011 · Cited by 145 · see citing works
Lipoprotein metabolism in chronic renal insufficiency
Saland, J. M., & Ginsberg, H. N. (2007) · Pediatric Nephrology · doi:10.1007/s00467-007-0467-5 · Cited by 80 · see citing works
Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease
Attman, P., Alaupovic, P., & Samuelsson, O. G. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07104.x · Cited by 60 · see citing works
Self-citationHadjivasilis, A., Kouis, P., Kousios, A., & Panayiotou, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030768 · Cited by 46 · see citing works
“In addition, two studies included patients with range of eGFR 10–70 mL/min/min, showing that GFR remained similar between patients receiving fenofibrate and patients receiving the control and that urinary protein excretion did not change after 12 months of follow up [36].”
BackgroundResultMANAGEMENT OF SELECTED LIPID ABNORMALITIES
Rader, D. J., & Rosas, S. E. (2000) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70206-6 · Cited by 36 · see citing works
Samuelsson, O. G., Attman, P., Knight‐Gibson, C., Mulec, H., Weiss, L. G., & Alaupovic, P. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.29883 · Cited by 28 · see citing works
Self-citationComorbidity and Cardiovascular Risk Factors in Patients With Chronic Kidney Disease
Paparello, J. J., Kshirsagar, A. V., & BATLLE, D. C. (2002) · Seminars in Nephrology · doi:10.1053/snep.2002.35969 · Cited by 22 · see citing works
Chronic Kidney Disease Stages 1–3
Ha, F., Ishani, A., Taylor, B. C., Nl, G., MacDonald, R. H., Rossini, D., Sadiq, S., Lankireddy, S., Kane, R. L., & Tj, W. (2012) · Europe PMC (PubMed Central) · Cited by 18 · see citing works
Peroxisome proliferator-activated receptor agonists in a battle against the aging kidney
Speeckaert, M. M., Vanfraechem, C., Speeckaert, R., & Delanghe, J. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.01.006 · Cited by 16 · see citing works
Low, J. H. M., Toh, D. W. K., Ng, M. T. T., Fam, J., Kua, E. H., & Kim, J. E. (2021) · Nutrients · doi:10.3390/nu13092936 · Cited by 14 · see citing works
Shearer, G. C., & Kaysen, G. A. (2006) · Kidney International · doi:10.1038/sj.ki.5000318 · Cited by 13 · see citing works
Liao, G., Wang, X., Li, Y., Chen, X., Huang, K., Bai, L., Ye, Y., & Peng, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010006 · Cited by 10 · see citing works
Naim, M. A. A. Z., Sumida, K., Streja, E., Thomas, F., Davis, R. L., Kalantar‐Zadeh, K., & Kovesdy, C. P. (2026) · Drugs · doi:10.1007/s40265-025-02275-w · Cited by 8 · see citing works
Rosas, S. E., Szapary, P. O., & Rader, D. J. (2003) · Cardiology Clinics · doi:10.1016/s0733-8651(03)00075-4 · Cited by 7 · see citing works
Effects of Gemfibrozil on Lipid and Hemostatic Factors in Capd Patients
Lee, M. S., Kim, S. M., Kim, S. B., & Lee, S. K. (1999) · Peritoneal Dialysis International · doi:10.1177/089686089901900319 · Cited by 4 · see citing works
Management of Dyslipidemia in Special Populations
Tovar, J. M., & Schering, D. B. (2006) · Journal of Pharmacy Practice · doi:10.1177/0897190006290045 · Cited by 3 · see citing works
MANAGEMENT OF SELECTED LIPID ABNORMALITIES
Rader, D. J., & Rosas, S. E. (2001) · Cardiology Clinics · doi:10.1016/s0733-8651(05)70215-0 · Cited by 3 · see citing works
Naim, M. A. A. Z., Thomas, F., Streja, E., Davis, R. L., Kalantar‐Zadeh, K., Sumida, K., & Kovesdy, C. P. (2026) · The Nephron journals/Nephron journals · doi:10.1159/000551276 · Cited by 2 · see citing works
Altered metabolism of apolipoprotein C.III: a contributor in chronic kidney disease?
Ooi, E. M. M., Watts, G. F., & Barrett, P. H. R. (2011) · Clinical Lipidology · doi:10.2217/clp.11.18
- Authors
- Samuelsson, O., Attman, P.-O., Knight-Gibson, C., Kron, B., Larsson, R., Mulec, H., Weiss, L., & Alaupovic, P.
- Affiliations
- University of Gothenburg (SE)
- Oklahoma Medical Research Foundation (US)
- ORCID
- Larsson, R.
- Venue
- Nephron
- Publisher
- S. Karger AG
- Published
- 2008-12-19
- Volume
- 75
- Issue
- 3
- Pages
- 286-294
- ISSN
- 1660-8151 (ISSN-L)
- 2235-3186
- OpenAlex
- W2067361204
- Cited by
- 23
- References
- 0
- Citations by year
- 2026: 2 · 2022: 2 · 2021: 1 · 2014: 2 · 2013: 1 · 2012: 2
- FWCI
- 0.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Nephron journals/Nephron journals (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- gemfibrozil, chronic renal insufficiency, triglyceride-rich lipoproteins, apolipoproteins, lipoprotein particles, nutrition counseling, lipid metabolism, apolipoprotein B, apolipoprotein C-III, apolipoprotein E, VLDL, low-density lipoprotein, high-density lipoprotein
- MeSH terms
- Hypolipidemic Agents, Apolipoproteins, Cholesterol, Female, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Lipids, Lipoproteins, Male, Middle Aged, Gemfibrozil
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
